MA-PRECISELY
14.12.2022 15:02:06 CET | Business Wire | Press release
Precisely, the global leader in data integrity, today announced the regional expansion of its unique location identifier, the PreciselyID, for its World Points of Interest (POI) data offering. Points of interest located in the US, Canada, Belgium, Luxembourg, the Netherlands, United Kingdom, Ireland, France, Sweden, and Singapore now benefit from accurate, standardized, and meaningful data – allowing businesses to streamline location-based decision-making across multiple regions of operation.
Disruption from the pandemic and other world events has had a lasting impact on many aspects of day-to-day life, including shopping habits, work location, and travel behaviors – making it even more important for businesses to be able to access accurate and current data on points of interest.
But keeping POI data fresh is no small feat, even for companies such as Google, who recently revealed that it removed seven million fake business profiles and prevented 12 million from being created throughout 2021 alone. Standardizing POI data is just as difficult; differences in address standards, language, character variations, or a lack of accurate address data, make it challenging for companies to effectively operationalize data from multiple regions.
Unlike other address identifiers on the market that associate a business name to an address, the PreciselyID is appended to both the location’s coordinates and the address and will remain constant over time. If a business closes and a new one opens in the same location, Precisely processes this change so that the PreciselyID will reflect the attributes for the new point of interest. As a result, businesses that use addresses as a primary data input will always have access to the most accurate data about any given location, enabling insights without needing geospatial tools or specialized skillsets.
“Businesses today need reliable answers about the world around them. If a clothing boutique closes, and the location becomes a coffee shop, it has an impact on the level of traffic, and types of shoppers, workers, and visitors to that area,” said Dan Adams, SVP – Data and Operations, at Precisely. “That’s why we associate the PreciselyID with an address and location, so our customers always have access to accurate, verified, and standardized data for detailed insights that matter to their business.”
POIs enabled with the PreciselyID have been cleansed, standardized, and verified by Precisely’s best-in-class geo addressing. As a result, organizations can quickly enrich records with accurate data while saving processing time and simplifying complex geospatial analysis. With access to a portfolio of over 400 datasets containing more than 9,000 attributes, Precisely customers can increase the accuracy, usability, and overall value of their business data and build context for faster, more confident decisions.
The regional expansion unlocks new capabilities for a wide variety of industries, including:
- Retail – Leveraging location insights for site selection and management, locating competition and demand to identify opportunities for new stores or consolidation
- Financial Services - Validating merchant data and achieving a 360-degree view of the changing landscape they operate in
- Insurance – Helping to understand adjacent risk – including whether a property is located near to a high-risk building, such as a chemical plant
- Telecommunications – Obtaining a full view into the places where people congregate, supporting telcos with their goal of providing high levels of coverage and keeping customers connected
- Public Sector – Understanding where people work, shop, and spend their leisure time, enhancing planning for public transport networks, emergency services, and planning
Precisely expects further expansion, with support for more countries added in the future. Learn more about how to seamlessly connect addresses, properties, and POI data with the PreciselyID here.
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
